Vascular Biogenics Ltd (VBLT)

[davidal66]

Right, and if they receive a single Avastin infusion and drop out, they are then included in the survival analysis. If they receive a single VB-111 infusion, they are included in the analysis. The trial had planned to enroll 252 and ended up enrolling 256 patients....so there can't have been too much of a responder overload. Obviously, those who remain in the trial after 5-6 months are by definition responders, but that is true in any trial of rGBM patients by definition considering the median overall survival.

The interesting post-hoc analysis might be comparing patients who received checkpoint inhibitors and VB-111 compared to those who did not.